Table of Content

1. Report Introduction

2. Advanced Renal Cell Carcinoma (RCC) Market Overview at a Glance
2.1. Market Share Distribution of Advanced Renal Cell Carcinoma (RCC) in 2017
2.2. Market Share Distribution of Advanced Renal Cell Carcinoma (RCC) in 2028

3. Disease Background and Overview: Advanced Renal Cell Carcinoma (RCC)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Advanced Renal Cell Carcinoma (RCC) in 7MM
4.3. Total Prevalent Patient Population of Advanced Renal Cell Carcinoma (RCC) in 7MM – By Countries

5. Epidemiology of Advanced Renal Cell Carcinoma (RCC) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC)
5.1.3. Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) *Indication Specific
5.1.4. Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) *Indication Specific
5.1.5. Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC)
5.1.6. Treatable Cases of the Advanced Renal Cell Carcinoma (RCC)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC)
5.4.3. Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) *
5.4.4. Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) *
5.4.5. Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC)
5.4.6. Treatable Cases of the Advanced Renal Cell Carcinoma (RCC)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC)
5.5.3. Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) *
5.5.4. Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) *
5.5.5. Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC)
5.5.6. Treatable Cases of the Advanced Renal Cell Carcinoma (RCC)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC)
5.6.3. Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) *
5.6.4. Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) *
5.6.5. Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC)
5.6.6. Treatable Cases of the Advanced Renal Cell Carcinoma (RCC)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC)
5.7.3. Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) *
5.7.4. Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) *
5.7.5. Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC)
5.7.6. Treatable Cases of the Advanced Renal Cell Carcinoma (RCC)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC)
5.8.3. Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) *
5.8.4. Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) *
5.8.5. Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC)
5.8.6. Treatable Cases of the Advanced Renal Cell Carcinoma (RCC)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC)
5.9.3. Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) *
5.9.4. Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) *
5.9.5. Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC)
5.9.6. Treatable Cases of the Advanced Renal Cell Carcinoma (RCC)

6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. Unmet Needs of the Advanced Renal Cell Carcinoma (RCC)

8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile

9. Pipeline Therapies – At a glance

10. Key Cross Competition

11. Emerging Therapies for Advanced Renal Cell Carcinoma (RCC)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile

12. Advanced Renal Cell Carcinoma (RCC) : 7MM Market Analysis
12.1. 7MM Market Size of Advanced Renal Cell Carcinoma (RCC)
12.2. 7MM Percentage Share of drugs marketed for Advanced Renal Cell Carcinoma (RCC)
12.3. 7MM Market Sales of Advanced Renal Cell Carcinoma (RCC) by Products

13. Advanced Renal Cell Carcinoma (RCC) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Advanced Renal Cell Carcinoma (RCC) in United States
13.1.2. Percentage Share of drugs marketed for Advanced Renal Cell Carcinoma (RCC) in United States
13.1.3. Market Sales of Advanced Renal Cell Carcinoma (RCC) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Advanced Renal Cell Carcinoma (RCC) in Germany
13.2.1.2. Percentage Share of drugs marketed for Advanced Renal Cell Carcinoma (RCC) in Germany
13.2.1.3. Market Sales of Advanced Renal Cell Carcinoma (RCC) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Advanced Renal Cell Carcinoma (RCC) in France
13.2.2.2. Percentage Share of drugs marketed for Advanced Renal Cell Carcinoma (RCC) in France
13.2.2.3. Market Sales of Advanced Renal Cell Carcinoma (RCC) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Advanced Renal Cell Carcinoma (RCC) in Italy
13.2.3.2. Percentage Share of drugs marketed for Advanced Renal Cell Carcinoma (RCC) in Italy
13.2.3.3. Market Sales of Advanced Renal Cell Carcinoma (RCC) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Advanced Renal Cell Carcinoma (RCC) in Spain
13.2.4.2. Percentage Share of drugs marketed for Advanced Renal Cell Carcinoma (RCC) in Spain
13.2.4.3. Market Sales of Advanced Renal Cell Carcinoma (RCC) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Advanced Renal Cell Carcinoma (RCC) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Advanced Renal Cell Carcinoma (RCC) in United Kingdom
13.2.5.3. Market Sales of Advanced Renal Cell Carcinoma (RCC) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Advanced Renal Cell Carcinoma (RCC) in Japan
13.3.2. Percentage Share of drugs marketed for Advanced Renal Cell Carcinoma (RCC) in Japan
13.3.3. Market Sales of Advanced Renal Cell Carcinoma (RCC) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
19. Disclaimer



List of Figures


Figure 1: Total Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in United States (2017-2028)
Figure 4: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in United States (2017-2028)
Figure 5: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in United States (2017-2028)
Figure 6: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in United States (2017-2028)
Figure 7: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in United States (2017-2028)
Figure 8: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in Germany (2017-2028)
Figure 9: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in Germany (2017-2028)
Figure 10: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in Germany (2017-2028)
Figure 11: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in Germany (2017-2028)
Figure 12: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in Germany (2017-2028)
Figure 13: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in France (2017-2028)
Figure 14: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in France (2017-2028)
Figure 15: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in France (2017-2028)
Figure 16: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in France (2017-2028)
Figure 17: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in France (2017-2028)
Figure 18: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in Italy (2017-2028)
Figure 19: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in Italy (2017-2028)
Figure 20: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in Italy (2017-2028)
Figure 21: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in Italy (2017-2028)
Figure 22: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in Italy (2017-2028)
Figure 23: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in Spain (2017-2028)
Figure 24: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in Spain (2017-2028)
Figure 25: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in Spain (2017-2028)
Figure 26: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in Spain (2017-2028)
Figure 27: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in Spain (2017-2028)
Figure 28: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in UK (2017-2028)
Figure 29: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in UK (2017-2028)
Figure 30: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in UK (2017-2028)
Figure 31: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in UK (2017-2028)
Figure 32: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in UK (2017-2028)
Figure 33: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in Japan (2017-2028)
Figure 34: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in Japan (2017-2028)
Figure 35: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in Japan (2017-2028)
Figure 36: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in Japan (2017-2028)
Figure 37: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in Japan (2017-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Figure 42:7MM- Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 43:7MM- Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 44: United States-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Figure 45: United States-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 46: United States-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 47: Germany-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Figure 48: Germany-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 49: Germany-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 50: France-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Figure 51: France-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 52: France-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 53: Italy-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Figure 54: Italy-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 55: Italy-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 56: Spain-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Figure 57: Spain-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 58: Spain-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 59:UK-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Figure 60:UK-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 61:UK-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 62: Japan-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Figure 63: Japan-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Figure 64: Japan-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)

 

List of Tables


Table 1: Total Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in 7MM
Table 2: Total Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in United States (2017-2028)
Table 4: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in United States (2017-2028)
Table 5: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in United States (2017-2028)
Table 6: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in United States (2017-2028)
Table 7: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in United States (2017-2028)
Table 8: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in Germany (2017-2028)
Table 9: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in Germany (2017-2028)
Table 10: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in Germany (2017-2028)
Table 11: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in Germany (2017-2028)
Table 12: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in Germany (2017-2028)
Table 13: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in France (2017-2028)
Table 14: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in France (2017-2028)
Table 15: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in France (2017-2028)
Table 16: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in France (2017-2028)
Table 17: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in France (2017-2028)
Table 18: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in Italy (2017-2028)
Table 19: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in Italy (2017-2028)
Table 20: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in Italy (2017-2028)
Table 21: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in Italy (2017-2028)
Table 22: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in Italy (2017-2028)
Table 23: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in Spain (2017-2028)
Table 24: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in Spain (2017-2028)
Table 25: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in Spain (2017-2028)
Table 26: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in Spain (2017-2028)
Table 27: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in Spain (2017-2028)
Table 28: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in UK (2017-2028)
Table 29: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in UK (2017-2028)
Table 30: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in UK (2017-2028)
Table 31: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in UK (2017-2028)
Table 32: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in UK (2017-2028)
Table 33: Prevalent/Incident Cases of the Advanced Renal Cell Carcinoma (RCC) in Japan (2017-2028)
Table 34: Sub-Type Specific cases of the Advanced Renal Cell Carcinoma (RCC) in Japan (2017-2028)
Table 35: Sex- Specific Cases of the Advanced Renal Cell Carcinoma (RCC) in Japan (2017-2028)
Table 36: Diagnosed Cases of the Advanced Renal Cell Carcinoma (RCC) in Japan (2017-2028)
Table 37: Treatable Cases of the Advanced Renal Cell Carcinoma (RCC) in Japan (2017-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Table 42:7MM- Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 43:7MM- Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 44: United States-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Table 45: United States-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 46: United States-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 47: Germany-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Table 48: Germany-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 49: Germany-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 50: France-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Table 51: France-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 52: France-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 53: Italy-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Table 54: Italy-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 55: Italy-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 56: Spain-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Table 57: Spain-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 58: Spain-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 59:UK-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Table 60:UK-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 61:UK-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 62: Japan-Market Size of Advanced Renal Cell Carcinoma (RCC) in USD MM (2017-2028)
Table 63: Japan-Market Share Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)
Table 64: Japan-Market Sales of Advanced Renal Cell Carcinoma (RCC) by Therapies in USD MM (2017-2028)